Mirai Medical has developed the CUTIS electrode for the delivery of pulsed electrical fields to cutaneous tumours.
The CUTIS electrode can be used on subcutaneous and cutaneous skin cancers examples of which include:
Non-melanoma skin cancers including BCC, SCC
Cutaneous metastases from other cancers eg. breast cancer
Rarer malignancies eg. Merkel Cell Carcinoma
Cutaneous B-cell lymphoma
Cutaneous gynaecological cancers
The design of the CUTIS electrode used alongside ePORE®has taken into account that ease of use and adaptability are key depending on the location of treatment.The CUTIS electrode is delivered to the skin via a slider deployment which, when the cap of the electrode retracts, the electrode can effectively deliver the pulsed electric field to the tissue.The potential benefits associated with CUTIS include:
Highly effective and delivers pulsed electrical fields
Does not destroy healthy tissue enabling cosmetic sensitivity
ePORE® therapy, EndoVE® and CUTIS are approved for commercialisation in the European Union, United Kingdom and Australia. ePORE® therapy, EndoVE® and CUTIS are not cleared by FDA for commercialisation in the USA.